Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of North Carolina
With
Cystic Fibrosis Foundation
Age
14–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Established diagnosis of CF
2 gene mutations identified, or
Sweat chloride \> 60 mmol/L, and
1 or more typical CF clinical features
Age \> 14 years
Able to perform spirometry and have post-bronchodilator FEV1 \> 50% of predicted at screening
Oxyhemoglobin saturation (by pulse oximetry) \> 92% on room air
Able to provide informed consent
You may not be if
Unstable lung disease:
FEV1 \> 15% below best clinical measurement within 6 months
Requirement for IV antibiotics within 4 weeks of screening
Requirement for any change in pulmonary medication within 2 weeks of screening
Evidence of reactive airways
Clinical diagnosis of asthma
-\> 15% increase in FEV1 after bronchodilator at screening
Hypertonic saline use within 2 weeks of screening
Unwilling or unable to either continue or discontinue cyclical therapies (e.g. inhaled tobramycin) for the 2 weeks prior to screening and the entire study period
Pregnancy, breast-feeding, or unwillingness to use barrier contraception during the entire study period
History of allergy or intolerance to amiloride, hypertonic saline, quinine, albuterol, or related compounds
Renal insufficiency (creatinine \> 1.5 mg/dl)
Hyperkalemia (K+ \> 5.0 meq/L)
Investigational drug use within 30 days of screening
Radiation exposure within the past year that would exceed Federal Regulations by participating in the study
